Skip to content
The People's CodeSearch
Menu

Changes to the Code

S. 475 · Alternatives to PAIN Act ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

42 U.S.C. § 1395w–102 Prescription drug benefits

+25 −2Shown
More for 42 U.S.C. § 1395w–102
Read § 1395w–102Only this section
4 changes the bill asks for here, 4 carried out
  1. Carried out:

    in paragraph (1)(A), in the matter preceding clause (i), by striking paragraphs (8) and (9) and inserting paragraphs (8), (9), and (10);

  2. Carried out:

    in paragraph (2)(A), in the matter preceding clause (i), by striking paragraphs (8) and (9) and inserting paragraphs (8), (9), and (10); and

  3. Carried out:

    by adding at the end the following new paragraph:(10) Treatment of cost-sharing for qualifying non-opioid pain management drugs.— (A) In general.— For plan years beginning on or after January 1, 2026, with respect to a covered part D drug that is a qualifying non-opioid pain management drug (as defined in subparagraph (B))— …

  4. Carried out:

    in subsection (c), by adding at the end the following new paragraph:(7) Treatment of cost-sharing for qualifying non-opioid pain management drugs.— The coverage is provided in accordance with subsection (b)(10)..

§ 1395w–102(b)Standard prescription drug coverage(1)–(2)

Start of § 1395w–102 to (a)(5) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(b)(b) Standard prescription drug coverage(b) Standard prescription drug coverage
For purposes of this part and part C, the term “standard prescription drug coverage” means coverage of covered part D drugs that meets the following requirements:For purposes of this part and part C, the term “standard prescription drug coverage” means coverage of covered part D drugs that meets the following requirements:
(1)(1) Deductible(1) Deductible
(1)(A)(A) In general(A) In general
Subject to paragraphs (8) and ([struck: 9]), the coverage has an annual deductible—Subject to paragraphs (8)[inserted: ,] [inserted: (9), ]and ([inserted: 10]), the coverage has an annual deductible—
(1)(A)(i)(i) (i)
for 2006, that is equal to $250; orfor 2006, that is equal to $250; or
(1)(A)(ii)(ii) (ii)
for a subsequent year, that is equal to the amount specified under this paragraph for the previous year increased by the percentage specified in paragraph (6) for the year involved.for a subsequent year, that is equal to the amount specified under this paragraph for the previous year increased by the percentage specified in paragraph (6) for the year involved.
(1)(B)(B) Rounding(B) Rounding
Any amount determined under subparagraph (A)(ii) that is not a multiple of $5 shall be rounded to the nearest multiple of $5.Any amount determined under subparagraph (A)(ii) that is not a multiple of $5 shall be rounded to the nearest multiple of $5.
(2)(2) Benefit structure(2) Benefit structure
(2)(A)(A) 25 percent coinsurance(A) 25 percent coinsurance
Subject to subparagraphs (C), (D), and (E) and paragraphs (8) and ([struck: 9]), the coverage has coinsurance (for costs above the annual deductible specified in paragraph (1) and up to the initial coverage limit under paragraph (3) for a year preceding 2025 and for costs above the annual deductible specified in paragraph (1) and up to the annual out-of-pocket threshold specified in paragraph (4)(B) for 2025 and each subsequent year) that is—Subject to subparagraphs (C), (D), and (E) and paragraphs (8)[inserted: ,] [inserted: (9), ]and ([inserted: 10]), the coverage has coinsurance (for costs above the annual deductible specified in paragraph (1) and up to the initial coverage limit under paragraph (3) for a year preceding 2025 and for costs above the annual deductible specified in paragraph (1) and up to the annual out-of-pocket threshold specified in paragraph (4)(B) for 2025 and each subsequent year) that is—
(2)(A)(i)(i) (i)
equal to 25 percent; orequal to 25 percent; or
(2)(A)(ii)(ii) (ii)
actuarially equivalent (using processes and methods established under section 1395w–111(c) of this title) to an average expected payment of 25 percent of such costs.actuarially equivalent (using processes and methods established under section 1395w–111(c) of this title) to an average expected payment of 25 percent of such costs.

§ 1395w–102(b)–(c)

(b)(2)(B)–(9)(D) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(b)(9)(D)(ii)(III)(III) (III)
an amount equal to 25 percent of the negotiated price of the covered insulin product under the prescription drug plan or MA–PD plan.an amount equal to 25 percent of the negotiated price of the covered insulin product under the prescription drug plan or MA–PD plan.
(b)(9)(E)(E) Special rule for first 3 months of 2023(E) Special rule for first 3 months of 2023
With respect to a month’s supply of a covered insulin product dispensed during the period beginning on January 1, 2023, and ending on March 31, 2023, a PDP sponsor offering a prescription drug plan or an MA organization offering an MA–PD plan shall reimburse an enrollee within 30 days for any cost-sharing paid by such enrollee that exceeds the cost-sharing applied by the prescription drug plan or MA–PD plan under subparagraph (B)(i) at the point-of-sale for such month’s supply.With respect to a month’s supply of a covered insulin product dispensed during the period beginning on January 1, 2023, and ending on March 31, 2023, a PDP sponsor offering a prescription drug plan or an MA organization offering an MA–PD plan shall reimburse an enrollee within 30 days for any cost-sharing paid by such enrollee that exceeds the cost-sharing applied by the prescription drug plan or MA–PD plan under subparagraph (B)(i) at the point-of-sale for such month’s supply.
(b)(10)(10) [inserted: Treatment of cost-sharing for qualifying non-opioid pain management drugs.—]
(b)(10)(A)(A) [inserted: In general.—]
[inserted: For plan years beginning on or after January 1, 2026, with respect to a covered part D drug that is a qualifying non-opioid pain management drug (as defined in subparagraph (B))—]
(b)(10)(A)(i)(i) [inserted: ]
[inserted: the deductible under paragraph (1) shall not apply; and]
(b)(10)(A)(ii)(ii) [inserted: ]
[inserted: such drug shall be placed on the lowest cost-sharing tier, if any, for purposes of determining the maximum co-insurance or other cost-sharing for such drug.]
(b)(10)(B)(B) [inserted: Qualifying non-opioid pain management drugs.—]
[inserted: In this paragraph, the term “qualifying non-opioid pain management drug” means a drug or biological product—]
(b)(10)(B)(i)(i) [inserted: ]
[inserted: that has a label indication approved by the Food and Drug Administration to reduce postoperative pain or any other form of acute pain;]
(b)(10)(B)(ii)(ii) [inserted: ]
[inserted: that does not act upon the body’s opioid receptors;]
(b)(10)(B)(iii)(iii) [inserted: ]
[inserted: for which there is no other drug or product that is—]
(b)(10)(B)(iii)(I)(I) [inserted: ]
[inserted: rated as therapeutically equivalent (under the Food and Drug Administration’s most recent publication of “Approved Drug Products with Therapeutic Equivalence Evaluations”); and]
(b)(10)(B)(iii)(II)(II) [inserted: ]
[inserted: sold or marketed in the United States; and]
(b)(10)(B)(iv)(iv) [inserted: ]
[inserted: for which the wholesale acquisition cost (as defined in section 1847A(c)(6)(B)), for a monthly supply does not exceed the monthly specialty-tier cost threshold as determined by the Secretary from time to time.]
(c)(c) Alternative prescription drug coverage requirements(c) Alternative prescription drug coverage requirements
A prescription drug plan or an MA–PD plan may provide a different prescription drug benefit design from standard prescription drug coverage so long as the Secretary determines (consistent with section 1395w–111(c) of this title) that the following requirements are met and the plan applies for, and receives, the approval of the Secretary for such benefit design:A prescription drug plan or an MA–PD plan may provide a different prescription drug benefit design from standard prescription drug coverage so long as the Secretary determines (consistent with section 1395w–111(c) of this title) that the following requirements are met and the plan applies for, and receives, the approval of the Secretary for such benefit design:
(c)(1)(1) Assuring at least actuarially equivalent coverage(1) Assuring at least actuarially equivalent coverage

§ 1395w–102(c)–(d)

(c)(1)(A)–(4) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(c)(5)(5) Treatment of cost-sharing for adult vaccines recommended by the Advisory Committee on Immunization Practices(5) Treatment of cost-sharing for adult vaccines recommended by the Advisory Committee on Immunization Practices
The coverage is in accordance with subsection (b)(8).The coverage is in accordance with subsection (b)(8).
(c)(6)(6) Treatment of cost-sharing for covered insulin products(6) Treatment of cost-sharing for covered insulin products
The coverage is provided in accordance with subsection (b)(9).The coverage is provided in accordance with subsection (b)(9).
(c)(7)(7) [inserted: Treatment of cost-sharing for qualifying non-opioid pain management drugs.—]
[inserted: The coverage is provided in accordance with subsection (b)(10).]
(d)(d) Access to negotiated prices(d) Access to negotiated prices
(d)(1)(1) Access(1) Access
(d)(1)(A)(A) In general(A) In general
Under qualified prescription drug coverage offered by a PDP sponsor offering a prescription drug plan or an MA organization offering an MA–PD plan, the sponsor or organization shall provide enrollees with access to negotiated prices used for payment for covered part D drugs, regardless of the fact that no benefits may be payable under the coverage with respect to such drugs because of the application of a deductible or other cost-sharing or, for a year preceding 2025, an initial coverage limit (described in subsection (b)(3)).Under qualified prescription drug coverage offered by a PDP sponsor offering a prescription drug plan or an MA organization offering an MA–PD plan, the sponsor or organization shall provide enrollees with access to negotiated prices used for payment for covered part D drugs, regardless of the fact that no benefits may be payable under the coverage with respect to such drugs because of the application of a deductible or other cost-sharing or, for a year preceding 2025, an initial coverage limit (described in subsection (b)(3)).

Rest of § 1395w–102 unchanged

42 U.S.C. § 1395w–104 Beneficiary protections for qualified prescription drug coverage

+11 −01 of 2 shown
More for 42 U.S.C. § 1395w–104
Read § 1395w–104Only this section
2 changes the bill asks for here, 1 carried out
  1. Not carried out:

    by redesignating paragraph (6), as added by section 50354 of division E of the Bipartisan Budget Act of 2018 (Public Law 115–123), as paragraph (7); and

    We can't read how this instruction is worded yet, so it isn't shown in the text.

    Technical detailno-pattern: redesignating paragraph (X), as added by section N of division e of the bipartisan budget act of N (REF), as paragraph (X); and
  2. Carried out:

    by adding at the end the following paragraph:(8) Prohibition on use of step therapy and prior authorization for qualifying non-opioid pain management drugs.— (A) In general.— For plan years beginning on or after January 1, 2026, a prescription drug plan or an MA–PD plan may not, with respect to a qualifying non-opioid pain management drug (as defined in section 1860D–2(b)(10)(B)) for which coverage is provided under such plan, impose any— (i) step therapy requirement under which an individual enrolled under such plan is required to use an opioid prior to receiving such drug; or (ii) prior authorization requirement. (B) Step therapy.— In this paragraph, the term step therapy means a drug therapy utilization management protocol or program that requires use of an alternative, preferred prescription drug or drugs before the plan approves coverage for the non-preferred drug therapy prescribed. (C) Prior authorization.— In this paragraph, the term prior authorization means any requirement to obtain approval from a plan prior to the furnishing of a drug..

§ 1395w–104(c)–(e)

Start of § 1395w–104 to (c)(6)(C)(iv) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(c)(6)(C)(v)(v) (v)
For any other purpose that the Secretary determines is necessary to include in order to protect the identity of individuals entitled to, or enrolled for, benefits under this subchapter and to protect the security of personal health information.For any other purpose that the Secretary determines is necessary to include in order to protect the identity of individuals entitled to, or enrolled for, benefits under this subchapter and to protect the security of personal health information.
(c)(6)(D)(D) Data described(D) Data described
The data described in this clause are standardized extracts (as determined by the Secretary) of claims data under parts A and B for items and services furnished under such parts for time periods specified by the Secretary. Such data shall include data as current as practicable.The data described in this clause are standardized extracts (as determined by the Secretary) of claims data under parts A and B for items and services furnished under such parts for time periods specified by the Secretary. Such data shall include data as current as practicable.
(c)(8)(8) [inserted: Prohibition on use of step therapy and prior authorization for qualifying non-opioid pain management drugs.—]
(c)(8)(A)(A) [inserted: In general.—]
[inserted: For plan years beginning on or after January 1, 2026, a prescription drug plan or an MA–PD plan may not, with respect to a qualifying non-opioid pain management drug (as defined in section 1860D–2(b)(10)(B)) for which coverage is provided under such plan, impose any—]
(c)(8)(A)(i)(i) [inserted: ]
[inserted: step therapy requirement under which an individual enrolled under such plan is required to use an opioid prior to receiving such drug; or]
(c)(8)(A)(ii)(ii) [inserted: ]
[inserted: prior authorization requirement.]
(c)(8)(B)(B) [inserted: Step therapy.—]
[inserted: In this paragraph, the term “step therapy” means a drug therapy utilization management protocol or program that requires use of an alternative, preferred prescription drug or drugs before the plan approves coverage for the non-preferred drug therapy prescribed.]
(c)(8)(C)(C) [inserted: Prior authorization.—]
[inserted: In this paragraph, the term “prior authorization” means any requirement to obtain approval from a plan prior to the furnishing of a drug.]
(d)(d) Consumer satisfaction surveys(d) Consumer satisfaction surveys
In order to provide for comparative information under section 1395w–101(c)(3)(A)(v) of this title, the Secretary shall conduct consumer satisfaction surveys with respect to PDP sponsors and prescription drug plans in a manner similar to the manner such surveys are conducted for MA organizations and MA plans under part C.In order to provide for comparative information under section 1395w–101(c)(3)(A)(v) of this title, the Secretary shall conduct consumer satisfaction surveys with respect to PDP sponsors and prescription drug plans in a manner similar to the manner such surveys are conducted for MA organizations and MA plans under part C.
(e)(e) Electronic prescription program(e) Electronic prescription program

Rest of § 1395w–104 unchanged

42 U.S.C. § 1395w–114 Premium and cost-sharing subsidies for low-income individuals

+6 −01 of 2 shown
More for 42 U.S.C. § 1395w–114
Read § 1395w–114Only this section
2 changes the bill asks for here, 1 carried out
  1. Not carried out:

    in paragraph (1)(D), in each of the clauses (ii) and (iii), by striking Subject to paragraph (6) and inserting Subject to paragraphs (6) and (7); and

    We can't read how this instruction is worded yet, so it isn't shown in the text.

    Technical detailno-pattern: in each of the clauses (X) and (X), by striking QTEXT and inserting QTEXT; and
  2. Carried out:

    by adding at the end the following new paragraph:(7) Treatment of cost-sharing or deductible for qualifying non-opioid pain management drugs.— For plan years beginning on or after January 1, 2026, with respect to a covered part D drug that is a qualifying non-opioid pain management drug (as defined in section …

§ 1395w–114(a)–(b)

Start of § 1395w–114 to (a)(6) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(a)(6)(A)(A) (A)
the deductible under section 1395w–102(b)(1) of this title shall not apply; andthe deductible under section 1395w–102(b)(1) of this title shall not apply; and
(a)(6)(B)(B) (B)
there shall be no cost-sharing under this section with respect to such vaccine.there shall be no cost-sharing under this section with respect to such vaccine.
(a)(7)(7) [inserted: Treatment of cost-sharing or deductible for qualifying non-opioid pain management drugs.—]
[inserted: For plan years beginning on or after January 1, 2026, with respect to a covered part D drug that is a qualifying non-opioid pain management drug (as defined in section 1860D–2(b)(10)(B))—]
(a)(7)(A)(A) [inserted: ]
[inserted: the deductible under section 1860D–2(b)(1) shall not apply; and]
(a)(7)(B)(B) [inserted: ]
[inserted: such drug shall be placed on the lowest cost-sharing tier, if any, for purposes of determining the maximum co-insurance or other cost-sharing for such drug.]
(b)(b) Premium subsidy amount(b) Premium subsidy amount
(b)(1)(1) In general(1) In general
The premium subsidy amount described in this subsection for a subsidy eligible individual residing in a PDP region and enrolled in a prescription drug plan or MA–PD plan is the low-income benchmark premium amount (as defined in paragraph (2)) for the PDP region in which the individual resides or, if greater, the amount specified in paragraph (3).The premium subsidy amount described in this subsection for a subsidy eligible individual residing in a PDP region and enrolled in a prescription drug plan or MA–PD plan is the low-income benchmark premium amount (as defined in paragraph (2)) for the PDP region in which the individual resides or, if greater, the amount specified in paragraph (3).

Rest of § 1395w–114 unchanged

Step through the changes